{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:52:39Z","timestamp":1793141559520,"version":"4.5.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,27]]},"DOI":"10.1097\/tp.0b013e3182962c84","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T12:01:28Z","timestamp":1371556888000},"page":"182-190","source":"Crossref","is-referenced-by-count":37,"title":["Analysis of Anti-HLA Antibodies in Sensitized Kidney Transplant Candidates Subjected to Desensitization with Intravenous Immunoglobulin and Rituximab"],"prefix":"10.1097","volume":"96","author":[{"given":"Andrew L.","family":"Lobashevsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy G.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad A.","family":"Mujtaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Goggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim E.","family":"Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.humimm.2005.01.027","article-title":"Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients.","volume":"66","author":"Akalin","year":"2005","journal-title":"Hum Immunol"},{"key":"R2-12-20210129","first-page":"525","article-title":"Is an acceptable mismatch program any better than post-transplant desensitization in donor-specific HLA antibodies plus kidney transplant recipients Am J T","volume":"12","author":"Brodin-Sartorius","year":"2012","journal-title":"ransplant"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2009.03004.x","article-title":"Making sense of desensitization.","volume":"10","author":"Gebel","year":"2010","journal-title":"Am J Transplant"},{"key":"R4-12-20210129","first-page":"221","article-title":"Intravenous immunoglobulins and kidney transplantation in patients with anti-HLA antibodies.","volume":"30","author":"Glotz","year":"2000","journal-title":"Adv Nephrol Necker Hosp"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1600-6143.2005.01214.x","article-title":"Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients.","volume":"6","author":"Jordan","year":"2006","journal-title":"Am J Transplant"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.transproceed.2011.12.028","article-title":"Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.","volume":"44","author":"Jordan","year":"2012","journal-title":"Transplant Proc"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trim.2009.03.002","article-title":"Effect of desensitization in solid organ transplant recipients depends on some cytokines genes polymorphism.","volume":"21","author":"Lobashevsky","year":"2009","journal-title":"Transpl Immunol"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.","volume":"9","author":"Perry","year":"2009","journal-title":"Am J Transplant"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/TP.0b013e3181d21e7f","article-title":"Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.","volume":"89","author":"Vo","year":"2010","journal-title":"Transplantation"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.humimm.2005.01.032","article-title":"Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.","volume":"66","author":"Zachary","year":"2005","journal-title":"Hum Immunol"},{"key":"R11-12-20210129","first-page":"223","article-title":"Report from a kidney paired donation centralized lab representing over 70 transplant programs and performing 325 cross matches resulting in 30 transplants.","volume":"9","author":"Blair","year":"2009","journal-title":"Am J Transplant"},{"key":"R12-12-20210129","first-page":"235","article-title":"Altruistic donation through the Alliance for Paired Donation.","volume":"8","author":"Rees","year":"2009","journal-title":"Clin Transpl"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-61779-842-9_15","article-title":"Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view.","volume":"882","author":"Susal","year":"2012","journal-title":"Methods Mol Biol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00007890-199703150-00001","article-title":"Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival T","volume":"63","author":"Piccotti","year":"1997","journal-title":"ransplantation"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/j.1600-6143.2009.02764.x","article-title":"Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody.","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.humimm.2004.07.003","article-title":"Differences in the response to treatment of antibodies by HLA class specificity.","volume":"65","author":"Leffell","year":"2004","journal-title":"Hum Immunol"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1586\/eci.11.10","article-title":"Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation.","volume":"7","author":"Jordan","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00007890-199908270-00027","article-title":"Repeat donor HLA-DR mismatches in renal transplantation: is the increased failure rate caused by noncytotoxic HLA-DR alloantibodies T","volume":"68","author":"Fuller","year":"1999","journal-title":"ransplantation"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/00007890-199706270-00018","article-title":"Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts.","volume":"63","author":"Fairchild","year":"1997","journal-title":"Transplantation"},{"key":"R20-12-20210129","first-page":"293","article-title":"Variable immunogenicity of HLA antigens.","volume":"11","author":"Eng","year":"2011","journal-title":"Am J Transplant"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.humimm.2010.06.140","article-title":"Human monoclonal antibody reactivity with HLA class I epitopes defined by eplet pairs.","volume":"71","author":"Duquesnoy","year":"2010","journal-title":"Hum Immunol"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MOT.0b013e3283028312","article-title":"Antibodies, isotypes and complement in allograft rejection.","volume":"13","author":"Bohming","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1600-6143.2011.03554.x","article-title":"Targeting B cells and antibody in transplantation.","volume":"11","author":"Clatworthy","year":"2011","journal-title":"Am J Transplant"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MOT.0b013e3283402cf4","article-title":"Targeting B cells in sensitized kidney transplant patients: state of the art and future perspectives.","volume":"15","author":"Snanoudj","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"key":"R25-12-20210129","first-page":"696","article-title":"Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation.","volume":"136","author":"Ferrari-Lacraz","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R27-12-20210129","first-page":"199","article-title":"Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation.","volume":"117","author":"Jordan","year":"2006","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/TP.0b013e3182590d2e","article-title":"Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients.","volume":"94","author":"Marfo","year":"2012","journal-title":"Transplantation"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival.","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-12-20210129","first-page":"1644","article-title":"Desensitization of HLA-incompatible kidney recipients.","volume":"365","author":"Morath","year":"2011","journal-title":"N Engl J Med"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1399-0039.2011.01638.x","article-title":"Current approaches to the management of highly sensitized kidney transplant patients.","volume":"77","author":"Susal","year":"2011","journal-title":"Tissue Antigens"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/01.TP.0000090868.88895.E0","article-title":"Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients.","volume":"76","author":"Zachary","year":"2003","journal-title":"Transplantation"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1600-6143.2008.02524.x","article-title":"Positive cross-match living donor kidney transplantation: longer-term outcomes.","volume":"9","author":"Haririan","year":"2009","journal-title":"Am J Transplant"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.TP.0000128516.82593.47","article-title":"Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.","volume":"78","author":"Gloor","year":"2004","journal-title":"Transplantation"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.08140910","article-title":"Desensitization protocols and their outcome.","volume":"6","author":"Marfo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R36-12-20210129","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ndt\/gfr429","article-title":"Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.","volume":"27","author":"Caro-Oleas","year":"2012","journal-title":"Nephr Dialysis Transplant"},{"key":"R37-12-20210129","first-page":"478","article-title":"Anti-allograft antibodies: some are harmful, some can be overcome, and some may be beneficial.","volume":"9","author":"Leffell","year":"2010","journal-title":"Discov Med"},{"key":"R38-12-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MOT.0b013e3283342798","article-title":"Antiallograft antibodies: relevance, detection, and monitoring.","volume":"15","author":"Leffell","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"key":"R39-12-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3343\/alm.2012.32.2.139","article-title":"Clinical relevance of pretransplant HLA class II donor-specific antibodies in renal transplantation patients with negative T-cell cytotoxicity crossmatches.","volume":"32","author":"Song","year":"2012","journal-title":"Ann Lab Med"},{"key":"R40-12-20210129","first-page":"36","article-title":"Are additional antibodies detected by Luminex single antigen testing clinically relevant A Collaborative Transplant Study report.","volume":"23","author":"Susal","year":"2010","journal-title":"Transpl Int"},{"key":"R41-12-20210129","first-page":"416","article-title":"Frequency of HLA-DP and MICA antibodies in hyperimmunized renal transplant candidates.","volume":"73","author":"Vittoraki","year":"2009","journal-title":"Tissue Antigens"},{"key":"R42-12-20210129","first-page":"588","article-title":"Transplantation of the broadly sensitized patient: what are the options Curr Opin Organ T","volume":"16","author":"Bohmig","year":"2011","journal-title":"ransplant"},{"key":"R43-12-20210129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.coi.2009.07.010","article-title":"Management of the highly sensitized patient.","volume":"21","author":"Claas","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"R44-12-20210129","first-page":"177","article-title":"A new approach for the transplantation of sensitized kidney graft recipients at a high risk of antibody-mediated graft loss.","volume":"22","author":"Morath","year":"2009","journal-title":"Transpl Int"},{"key":"R45-12-20210129","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.transproceed.2011.02.074","article-title":"Kidney transplantation for high-risk sensitized patientsthe Heidelberg algorithm.","volume":"43","author":"Morath","year":"2011","journal-title":"Transplant Proc"},{"key":"R46-12-20210129","first-page":"467","article-title":"Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch Langenbecks Arch S","volume":"396","author":"Morath","year":"2011","journal-title":"urg"},{"key":"R47-12-20210129","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1432-2277.2012.01447.x","article-title":"Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy.","volume":"25","author":"Morath","year":"2012","journal-title":"Transpl Int"},{"key":"R48-12-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1600-6143.2009.02968.x","article-title":"Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.","volume":"10","author":"Sberro-Soussan","year":"2010","journal-title":"Am J Transplant"},{"key":"R49-12-20210129","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/TP.0b013e3181856f98","article-title":"Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.","volume":"86","author":"Reinsmoen","year":"2008","journal-title":"Transplantation"},{"key":"R50-12-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation.","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R51-12-20210129","first-page":"19","article-title":"Limitations of rituximabIVIg desensitization protocol in kidney transplantation; is this better than a tincture of time Ann T","volume":"16","author":"Kozlowski","year":"2011","journal-title":"ransplant"},{"key":"R52-12-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1432-2277.2010.01138.x","article-title":"Desensitization for renal transplantation: depletion of donor-specific anti-HLA antibodies, preservation of memory antibodies, and clinical risks.","volume":"24","author":"Rogers","year":"2011","journal-title":"Transpl Int"},{"key":"R53-12-20210129","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/TP.0b013e3181b7ccc6","article-title":"Functional genomic analysis of peripheral blood during early acute renal allograft rejection.","volume":"88","author":"Gunther","year":"2009","journal-title":"Transplantation"},{"key":"R54-12-20210129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/TP.0b013e3182029b16","article-title":"Effects of sample timing and treatment on gene expression in early acute renal allograft rejection.","volume":"91","author":"Gunther","year":"2011","journal-title":"Transplantation"},{"key":"R55-12-20210129","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1172\/JCI39933","article-title":"Identification of a B cell signature associated with renal transplant tolerance in humans.","volume":"120","author":"Newell","year":"2010","journal-title":"J Clin Invest"},{"key":"R56-12-20210129","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/j.lpm.2012.05.021","article-title":"B-cell populations and sub-populations in Sjogrens syndrome.","volume":"41","author":"Hamza","year":"2012","journal-title":"Presse Med"},{"key":"R57-12-20210129","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1111\/j.1600-6143.2012.04194.x","article-title":"BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies.","volume":"12","author":"Thibault-Espitia","year":"2012","journal-title":"Am J Transplant"},{"key":"R58-12-20210129","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/TP.0b013e3181bbba1a","article-title":"BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.","volume":"88","author":"Zarkhin","year":"2009","journal-title":"Transplantation"},{"key":"R59-12-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-6143.2011.03833.x","article-title":"In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.","volume":"12","author":"Kamburova","year":"2012","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0b013e3182962c84","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:33:19Z","timestamp":1620977599000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201307270-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,27]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3182962c84","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,27]]}}}